Kiniksa Pharmaceuticals, Ltd.
NASDAQ:KNSA
25.27 (USD) • At close September 18, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Kiniksa Pharmaceuticals, Ltd. |
Symbool | KNSA |
Munteenheid | USD |
Prijs | 25.27 |
Beurswaarde | 1,800,328,653 |
Dividendpercentage | 0% |
52-weken bereik | 14.12 - 27.92 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. Sanj K. Patel |
Website | https://www.kiniksa.com |
An error occurred while fetching data.
Over Kiniksa Pharmaceuticals, Ltd.
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)